Axelife, a French Healthcare Association member, continues to assert its international leadership in the field of cardiovascular health. Its recent involvement in two major scientific events illustrates its essential role in the prevention and treatment of arterial hypertension (AH), as well as in research into arterial stiffness.
A strong presence at the HTA 2025 Meeting
The first HTA 2025 Meeting, held in conjunction with the Cardio-Renal Metabolic Meeting in Tabarka on 6 and 8 February, brought together researchers, clinicians and healthcare professionals to highlight the latest advances in the complex interactions between the cardiovascular, renal and metabolic systems.
Axelife distinguished itself by presenting its innovative solutions for assessing arterial stiffness, a key cardiovascular risk factor, to a wide audience. During the event, fruitful exchanges with international experts, notably from the Forces de Sécurité Intérieure – La Marta hospital in Tunisia, provided an opportunity to share best practice and explore new therapeutic approaches. A practical workshop on 7 February highlighted Axelife’s flagship innovation in arterial age measurement.
Professor Roland Asmar, a leading figure in arterial stiffness research, demonstrated the importance of Axelife‘s devices in improving cardiovascular monitoring. In addition, Michael Harrison represented the company on a stand alongside KT BIO and THERA, consolidating the French company’s presence on the international stage.
Finally, discussions focused on the integration of arterial monitoring technologies into clinical practice, with an emphasis on their usefulness in the prevention of cardiovascular and metabolic diseases.
Axelife at the 2024 Hypertension Days
This event comes shortly after Axelife’s active participation in the Journées de l’Hypertension Artérielle (JHTA) 2024, another key scientific event organised by the Société Française de l’Hypertension Artérielle. Last December, the event brought together international experts to discuss advances in arterial stiffness and cardiovascular prevention.
Professor Roland Asmar also took part in this captivating symposium, highlighting the latest European advances in this field.
A highlight of the JHTA 2024 was the practical workshop on measuring arterial stiffness, led by Dr Rosa Maria Bruno and Dr Davide Agnoletti. This workshop enabled healthcare professionals from all over the world to discover an innovative medical device developed by Axelife. This technology represents a major advance in cardiovascular risk assessment and illustrates French excellence in medical innovation.
The JHTA 2024 was also an opportunity to present the results of new studies on the accuracy and effectiveness of arterial stiffness screening tools, reinforcing Axelife’s position as a leader in the field while strengthening worldwide interprofessional collaboration around hypertension and cardiovascular health.
With a strategy focused on scientific excellence, development, research and international knowledge sharing, Axelife is establishing itself as a key French player in the global fight against hypertension.
